Dr Temy Mo Yin Mok (莫慕賢醫生/博士)

MBBS (HKU), MD (HKU), FHKCP, FHKAM (Rheumatology), FRCP (Glasgow, Edinburgh), FRCPA (Immunology)

Associate Professor

Dr Temy Mo Yin Mok

Contact Information

Office: 1A-102, 1/F, Block 1,
To Yuen Building
Phone: +852 3442-2714
Fax: +852 3442-0549
Email: temy.mok@cityu.edu.hk
Web: CityU Scholars

Research Interests

  • Autoimmune and rheumatic diseases
  • Systemic lupus erythematosus
  • Murine lupus
  • Innate immunity
  • Biomarker


Dr Mok graduated with her MBBS from the University of Hong Kong in 1992. She trained in rheumatology at the Department of Medicine, Queen Mary Hospital, Hong Kong from 1996–1999. She obtained Croucher Foundation scholarship to pursue clinical and laboratory training on systemic lupus erythematosus under supervision of Prof. David Isenberg at the Bloomsbury rheumatology unit of the University College London in 1998/1999. She became fellow in rheumatology and advanced internal medicine at the Hong Kong College of Physicians and Hong Kong Academy of Medicine in 1999/2000. From 2001–2007, she enrolled in part-time training in Immunology under the Royal College of Pathologists of Australasia and obtained her fellowship in 2007. In the same year, she joined the Faculty of Medicine, the University of Hong Kong as clinical assistant professor. Her MD research thesis was awarded by the University of Hong Kong in 2011. She was visiting scholar at the Institute of Infection, Immunity and Inflammation, University of Glasgow, and the Centre for Autoimmunity and Musculoskeletal diseases, The Feinstein Institute for Research, New York from 2011–2012, and Program of Clinical and Molecular Medicine at Harvard Medical School in 2019. She became associate professor at the Department of Biomedical Sciences of the City University of Hong Kong since August 2016. She has over 90 peer-reviewed research articles and has supervised 7 research postgraduate students. She is associate editor of the peer-reviewed journal International Journal of Rheumatic Diseases. She is council member and convenor of the scientific committee of the Hong Kong Arthritis & Rheumatism Foundation. She also serves as adviser for the Hong Kong Society of Rehabilitation and many local rheumatology patient self-help groups.

Research Interests

Dr Mok’s research interests include:

  • Pathogenesis and immunotherapy of systemic lupus erythematosus (SLE) with focus on the role of dendritic cells, macrophages, inflammatory cytokines and murine models
  • Neuropsychiatric manifestations of SLE
  • Immunogenetics and biomarkers for clinical manifestations of rheumatic diseases

Selected Publications

Immunological aspects of rheumatic diseases

  1. Yeung KS, Chung BH, Choufani S, Mok MY, et al. Genome-wide DNA methylation analysis of Chinese patients with systemic lupus erythematosus identified hypomethylation in genes related to the type I interferon pathway. PLoS One 2017;21:12
  2. Wu HJ, Lo Y, Chan A, Law KS, Mok MY. Bone marrow derived dendritic cells modified by lentiviral-mediated RelB shRNA possess tolerogenic phenotype and functions on lupus splenic lymphocytes. Immunology 2016, Jun 9 [Epub ahead of print]
  3. Mok MY, Shoenfeld Y. Recent advances and current state of immunotherapy in systemic lupus erythematosus. Expert opinion on biological therapy, 2016;16:927-39
  4. Mok MY. Tolerogenic dendritic cells: Role and therapeutic implications in systemic lupus erythematosus. Invited Review. International Journal of Rheumatic Diseases 2015;18:250-9
  5. Wu HJ, Lo Y, Chan A, Lau CS, Lu L, Mok MY. Alternatively activated dendritic cells derived from systemic lupus erythematosus patients have tolerogenic phenotype and function. Clinical Immunology 2015; 156:43-57
  6. Zhang Y, Yang W, Mok CC, Chan TM, Wong RW, Mok MY, et al. Two missense variants in UHRF1P1 are independently associated with systemic lupus erythematosus in Hong Kong Chinese. Genes & Immunity 2011;12:23104
  7. Mok MY, Wu HJ, Lo Y, Lau CS. Serum The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. Journal of Rheumatology 2010,37:2046-52
  8. Shen N, Fu Q, Deng Y, Q XX, Zhao J, Kaufman K, Wu YL, Yu , Tan YJ, Chen YU, Yang W, Wong M, Kawasaki A, Tsuchiya N, Sumida T, Kawaguchi Y, Howe HS, Mok MY, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proceedings of National Academy of Sciences of the United States of America 2010;107:15838-43
  9. Mok MY, Huang FP, Ip WK, Lo Y, Wong FY, Chan YT, Lam KF, Xu D. Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology 2010,49:520-7
  10. Nie YJ, Lau CS, Lie AKW, Chan GCF, Mok MY. Defective phenotype of mesenchymalstem cells in patients with systemic lupus erythematosus. Lupus 2010;19:850-9
  11. Mok MY. The immunological basis of B cell therapy in systemic lupus erythematosus. International Journal of Rheumatic Diseases 2010;13:3-11
  12. Mok MY, Yiu KH, Wong CY, Qiuwaxi J, Lai WH, Lo Y, Wong WS, Tse HF, Lau CS. Low circulating level of CD133+KDR+ cells in patients with systemic sclerosis. Clinical and Experimental Rheumatology 2010,28:S19-25
  13. Yang W, Zhao M, Hirankarn N, Lau CS, Mok CC, Chan TM, Wong RW, Lee KW, Mok MY, et al. ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Human Molecular Genetics 2009;18:2063-70

Clinical aspects of rheumatic diseases

  1. Ng AL, Choy BN, Chan TC, Wong IY, Lai JS, *Mok MY. Comparison of tear osmolarity in rheumatoid arthritis patients with and without secondary Sjogren’s syndrome. Cornea 2017 May [Epub ahead of print]
  2. Golder V, Kandane-Rathnayake R, Hoi AY, (another 7 authors), Mok MY, et al ; Asia-Pacific Lupus Collaboration. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther 2017; 19:62
  3. GEO-RA group. Latitude gradient influences the age of onset of rheumatoid arthritis: a worldwide survey. Clin Rheumatol 2017;36:485-97
  4. Golder V,   Kandane-Rathnayake R, Hoi AY, (another 8 authors), Mok MY, et al ; Asia-Pacific Lupus Collaboration. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther 2016; 18:260
  5. Gao Y, Cheung TF, Gao J, Lau EY, Wan JH, Mok MY. Evaluation of cognitive function by electrophysiological study in systemic lupus erythematosus patients with previous neuropsychiatric involvement. Clinical EEG & Neuroscience 2016, in press
  6. Xu XP, Hui E, Mok MY, Jian J, Zhu J, Lau CS, Mak HK. Impaired small-world structural brain network in patients with neuropsychiatric systemic lupus erythematosus. American Journal Neuroradiology 2017; 38:64-70
  7. Gao Y, Wan HY, Lau YY, Lau CS, Mok MY. Cognitive function in systemic lupus erythematosus patients with past history of neuropsychiatric manifestations: A longitudinal study. Lupus 2016;25:637-44
  8. Chen JY, Wu YL, Mok MY, Wu YJ,….(another 13 authors), Yu CY. Effects of complement C4 gene copy-number variations, size dichotomy and C4A-deficiency on genetic risk and clinical presentation of East-Asian SLE. Arthritis & Rheumatology 2016, 68:1442-53
  9. Gao Y, Lo Y, Mok MY. Symptoms of attention deficit hyperactivity disorder in patients with systemic lupus erythematosus. Lupus 2015;24:1498-504
  10. Leung WK, Chu CH, Mok MY, Yeung KW, Ng SK. Periodontal status of adults with systemic sclerosis: case-control study. Journal of Periodontology 2011; 82:1140-5
  11. Mok MY, Lau CS, Chiu SS, Tso A, Lo Y, Law LSC, Mak MF, Wong WS, Khong PL, Lam KSL. Systemic Sclerosis is an independent predictive factor for coronary atherosclerosis. Arthritis & Rheumatism 2011;63:1387-95
  12. Yiu KH, Tse HF, Mok MY, Lau CS. Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians. Nature Reviews of Rheumatology 2011;7:609-18
  13. Mok MY, Lau CS. The burden and measurement of cardiovascular disease in systemic sclerosis. Nature Reviews Rheumatology 2010;6:430-4
  14. Chu CH, Yeung CMK, Lai IA, Leung WK, Mok MY. Oral health and features of Chinese people with systemic sclerosis. Clinical Oral Investigations 2010,15:931-9
  15. Mok MY, Chiu SS, Lo Y, Mak KF, Wong WS, Khong PL, Lau CS. Coronary atherosclerosis using CT coronary angiogram in patients with systemic sclerosis. Scandinavian Journal of Rheumatology 2009;38:381-5
  16. Mok MY, Chan EY, Wong WS, Lau CS. Intrathecal immunoglobulin production by IgG index and oligoclonal bands in various neuropsychiatric manifestations in systemic lupus erythematosus. Annals of Rheumatic Diseases 2007;66:846-7
  17. Mok MY, BMY Cheung, Y Lo, RYH Leung, Wong WS, Lau CS. Elevated plasma adrenomedullin in patients with systemic sclerosis with pulmonary hypertension. Journal of Rheumatology 2007;34:2224-9
  18. Mok MY, Fung PC, Ooi C, Tse HF, Wong Y, Lam YM, Wong WS, Lau CS. Serum nitric oxide and disease activity in patients with systemic sclerosis. Clinical Rheumatology 2008;27:315-22
  19. Mok MY, Chan EY, Fong DY, Leung KF, Wong WS, Lau CS. Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus. Journal of Rheumatology 2005; 32: 622-8
  20. Mok MY, Leung PY, Lao TH, Lo Y, Chan TM, Wong WS, Lau CS. Clinical predictors of fetal and maternal outcome in Chinese patients with systemic lupus erythematosus. Annals of Rheumatic Diseases 2004; 63:1705-6
  21. Mok MY, Jack DL, Lau CS, Fong DYT, Turner MW, Isenberg DA, Lydyard PM. Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 2004; 13: 522-8
  22. McMillan AS, Leung KCM, Wong MCM, Leung WK, Lau CS, Mok TMY. Impact of Sjogren’s syndrome on oral health-related quality of life in southern Chinese. Journal of Oral Rehabilitation 2004;31:653-9
  23. Mok MY, Ng WL, Yuen MF, Wong RWS, Lau CS. Safety of disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients with chronic viral hepatitis. Clinical and Experimental Rheumatology 2000;18:363-8
  24. Mok MY, Farewell VT, Isenberg DA. Risk factors for avascular necrosis in systemic lupus erythematosus: Is there a role for antiphospholipid antibodies? Annals of Rheumatic diseases 2000;59:462-7

Position Availability

Interested applicants for research assistant/associate and post-doctoral fellow for research work in rheumatology/autoimmunity are welcome. Recruitment for postgraduate studentship under Department of Biomedical Sciences, or its interdisciplinary PhD programme with Veterinary Sciences are open. Please send your CV and summary of past research experience to Dr Temy Mok: temy.mok@cityu.edu.hk.